Oxford University

or Find Staff here

Results for University of Oxford

Results 1 - 10 of 35 for govindin .

Your query has been expanded to: govindan.  Search for govindin instead.

Sort by date, Sort by relevance.

Results

1. Ethnic Minorities – Keble College JCR

Ethnic Minorities. Arnya Govindan. As the Ethnic Minorities representatives, I’m responsible for making sure that Keble remains an enjoyable environment for students in college who identify as an ethnic minority. ... arnya.govindan@keble.ox.ac.uk.

jcr.keble.ox.ac.uk/ethnicminorities/- 25k - Cached

2. Comments on: XAMPP (1.8.1) on Windows 8 – Apache not starting as Port 80 “in use by system”

https://learntech.imsu.ox.ac.uk/blog/xampp-1-8-1-on-windows-8-apache-not-starting-as-port-80-in-use-by-system/ Learning and teaching with technology in the medical sciences Thu, 26 Mar 2020 16:28:19 0000 hourly 1 https://wordpress.org/?v=5.1.5 https:

learntech.imsu.ox.ac.uk/blog/xampp-1-8-1-on-windows-8-apache-not-starting-as-port-80-in-use-by-system/feed/- 8k - 26 Mar 2020 - Cached

3. 2019-2020 JCR Committee – Keble College JCR

Oliver Hardman. Alex Sommerville-Large. Nat Nickells. Maya Raman Jones. Arnya Govindan.

jcr.keble.ox.ac.uk/about-the-jcr/committee/- 37k - Cached

4. Nab-Paclitaxel plus Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+ — Department of Oncology

Govindan R., Dols MC., Aix S., Postmus PE., Lewanski C., Bennouna J., Fischer J., Vidal O., Stewart D., Ardizoni A., Weaver J., Wolfsteiner M., Reck M., Talbot D., Morgensztern D., Ong

www.oncology.ox.ac.uk/publications/995977- 114k - Cached

5. https://www.cs.ox.ac.uk/files/2170/SensysPoster06_Trigoni.pdf

merging. 4 References. [1] C. Intanagonwiwat, R. Govindan, and D. Estrin. Di-rected diffusion: a scalable and robust communicationparadigm for sensor networks. ... In Mobicom, pages181–190, 1998. [5] C. Yu, R. Govindan, and D.

www.cs.ox.ac.uk/files/2170/SensysPoster06_Trigoni.pdf- 87k - 5 Oct 2015 - Cached

6. vitapc

Govindan (1998) Currently working in finance. E. Perevalov (1998) Currently Associate Professor at Lehigh University.

www.maths.ox.ac.uk/system/files/user-cvs/candelas.pdf- 95k - 26 Aug 2010 - Cached

7. Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+) — Department of Oncology

Morgensztern D., Govindan R., Cobo M., Ponce Aix S., Postmus PE., Lewanski C., Bennouna J., Fischer J., Juan-Vidal O., Stewart D., Ardizzoni A., Bhore R., Wolfsteiner M., Reck M., Talbot

www.oncology.ox.ac.uk/publications/958268- 114k - Cached

8. ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) — Department of Oncology

Morgensztern D., Ong TJ., Dols MC., Aix SP., Postmus PE., Lewanski C., Bennouna J., Fischer JR., Vidal OJ., Stewart DJ., Fasola G., Ardizoni A., Weaver J., Wolfsteiner M., Talbot D., Govindan

www.oncology.ox.ac.uk/publications/738403- 113k - Cached

9. Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+ — Department of Oncology

2L+. Talbot D., Govindan R., Cobo M., Ponce Aix S., Postmus PE., Lewanski C., Bennouna J., Fischer J., Juan-Vidal O., Stewart D., Ardizzoni A., Bhore R., Wolfsteiner M., Reck M.,

www.oncology.ox.ac.uk/publications/958269- 114k - Cached

10. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). — Department of Oncology

Ong T., Govindan R., On Behalf Of The Abound L Investigators None.

www.oncology.ox.ac.uk/publications/942552- 122k - Cached

Result Page

1 , 2 , 3 , 4 , Next .




Enquiries to Webmaster | Powered by Funnelback Search